156 results
Page 2 of 8
SC TO-C
EX-99.1
ughu81rn2v2d2
3 Oct 23
Information about tender offer
4:30pm
SC TO-C
u0rt 5xt7gm
3 Oct 23
Information about tender offer
4:30pm
SC14D9C
EX-2.1
b88uwml9izy1
3 Oct 23
Written communication relating to third party tender offer
7:37am
SC14D9C
EX-99.4
3mqke smx
3 Oct 23
Written communication relating to third party tender offer
7:37am
SC14D9C
k0gt7kbyyc 0x
3 Oct 23
Written communication relating to third party tender offer
7:37am
8-K
EX-2.1
b5rscoy
3 Oct 23
Tender and Support Agreement
7:35am
8-K
3f6zo5dotyipwyj9z420
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-99.4
8hp3d
3 Oct 23
Tender and Support Agreement
7:35am
8-K
EX-99.1
x0jp8y q86
14 Aug 23
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
7:21am
ARS
qe142effm0w3uy ut
1 May 23
Annual report to shareholders
1:52pm
8-K
EX-1.1
ls1te0s 38kw3xnf
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
424B5
doet8
14 Sep 22
Prospectus supplement for primary offering
4:12pm
424B5
tkwdtp0n slss4hq29az
13 Sep 22
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
qfpp zsf66o6e
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am